Sodium valproate in schizophrenia: some biochemical correlates

Sodium valproate given in doses of 750-3000 mg daily to eight schizophrenic patients produced a qualitatively similar increase in symptoms in five. CSF showed no significant change in gamma-amino-butyric acid or methoxy hydroxyphenyl glycol, but homovanillic acid increased non-significantly in five...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of psychiatry Vol. 137; p. 240
Main Authors Lautin, A, Angrist, B, Stanley, M, Gershon, S, Heckl, K, Karobath, M
Format Journal Article
LanguageEnglish
Published England 01.09.1980
Subjects
Adult
Clinical Trials as Topic
gamma-Aminobutyric Acid - cerebrospinal fluid
Homovanillic Acid - cerebrospinal fluid
Humans
Male
Methoxyhydroxyphenylglycol - cerebrospinal fluid
Middle Aged
Schizophrenia - cerebrospinal fluid
Schizophrenia - drug therapy
Valproic Acid - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Sodium valproate given in doses of 750-3000 mg daily to eight schizophrenic patients produced a qualitatively similar increase in symptoms in five. CSF showed no significant change in gamma-amino-butyric acid or methoxy hydroxyphenyl glycol, but homovanillic acid increased non-significantly in five patients.
ISSN:0007-1250
DOI:10.1192/bjp.137.3.240